EyeGate Reports Full-year 2015 Financial Results and Provides Business Update
29. März 2016 16:45 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Acquires Jade Therapeutics
07. März 2016 16:05 ET
|
EyeGate Pharmaceuticals, Inc.
Transaction enhances development pipeline with addition of new ophthalmic platform technology. First Jade product to enter clinic later this year.WALTHAM, Mass., March 07, 2016 (GLOBE NEWSWIRE)...
EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437
02. März 2016 08:00 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
19. Januar 2016 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 12th Annual Investor Conference
14. Januar 2016 09:49 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on...
EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update
12. November 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients
05. November 2015 08:45 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Receives USPTO Notice of Allowance for Next Generation of Proprietary Iontophoretic Delivery System
15. Oktober 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
Patent to Provide Broad Coverage for EyeGate II® Delivery System with Pre-filled Drug Applicator
Also,Patent Covering Proprietary Dexamethasone Phosphate Pharmaceutical Formulation...
Eyegate Pharmaceuticals to Present at the 17th Rodman and Renshaw 2015 Annual Global Investment Conference
01. September 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing...
Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
05. August 2015 13:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing...